Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2195-2206

  Cai, Shanbao ^a,b   Wang, Haiyan ^a,b   Bailey, Barbara ^a,b,c   Ernstberger, Aaron ^a,b   Juliar, Beth E ^b,d   Sinn, Anthony L ^b,c   Chan, Rebecca J ^a,b,e   Jones, David R ^b,f   Mayo, Lindsey D ^a,b   Baluyut, Arthur R ^g   Goebel, W Scott ^a,b   Pollok, Karen E ^a,b,c,f  

^a RILEY HOSPITAL FOR CHILDREN   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c In Vivo Therapeutics Core   (United States)

^d IUSCC   (United States)

^e Department of Medical and Molecular Genetics ^*  (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ST VINCENT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW CELL; BONE MARROW RESCUE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSE INCREASE; GLIOMA; GLIOMA CELL; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LYMPHOID CELL; MOUSE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; SCID MOUSE; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE MARROW CELLS; CELL LINE, TUMOR; CORD BLOOD STEM CELL TRANSPLANTATION; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; GUANINE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; SURVIVAL ANALYSIS; TRANSPLANTATION CHIMERA; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79954582411     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1959     Document Type: Article

References (51)

1. Hollingshead MG. Antitumor efficacy testing in rodents. J Natl Cancer Inst 2008;100:1500-10.
2. Erickson-Miller CL, May RD, Tomaszewski J, Osborn B, Murphy MJ, Page JG, et al. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol 1997;39:467-72. (Pubitemid 27078134)
3. Kurtzberg LS, Roth SD, Bagley RG, Rouleau C, Yao M, Crawford JL, et al. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents. Cancer Chemother Pharmacol 2009;64:1029-38.
4. Masubuchi N, May RD, Atsumi R. A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay. Clin Cancer Res 2004;10:6722-31. (Pubitemid 39346570)
5. Pessina A, Albella B, Bayo M, Bueren J, Brantom P, Casati S, et al. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol Sci 2003;75:355-67. (Pubitemid 37220283)
6. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005;174:6477-89. (Pubitemid 40663843)
7. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000;18:3522-8.
8. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005;23:7178-87.
9. 6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 2009;27:1262-7.
10. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, et al. Phase II trial of carmustine plus O (6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002;20:2277-83. (Pubitemid 34441654)
11. 6-alkylguanine-DNA alkyltransferase. Cancer Research 1994;54:5123-30.
12. 6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. Cancer Chemother Pharmacol 1994;35:121-6. (Pubitemid 24359732)
13. 6- benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 1990;87:5368-72.
14. 6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun 1990;2:371-7.
15. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006;12:328-31. (Pubitemid 43166117)
16. 6-benzylguanine on the sensitivity of human tumor xenografts to 1, 3-bis (2-chloroethyl)-1- nitrosourea and on DNA interstrand cross-link formation. Cancer Res 1992;52:1171-5.
17. Buschfort-Papewalis C, Moritz T, Liedert B, Thomale J. Down-regulation of DNA repair in human CD34 (+) progenitor cells corresponds to increased drug sensitivity and apoptotic response. Blood 2002;100:845-53. (Pubitemid 34832609)
18. Kreklau EL, Pollok KE, Bailey BJ, Liu N, Hartwell JR, Williams DA, et al. Hematopoietic expression of O (6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O (6)-benzylguanine and 1, 3-bis-(2-chloroethyl)-1-nitrosourea. Mol Cancer Ther 2003;2:1321-9.
19. Cai S, Hartwell JR, Cooper RJ, Juliar BE, Kreklau E, Abonour R, et al. In vivo effects of myeloablative alkylator therapy on survival and differentiation of MGMTP140K-transduced human G-CSF-mobilized peripheral blood cells. Mol Ther 2006;13:1016-26.
20. Chen ZP, Pan J, Huang Q, Sun ZF, Zhou LY, Wang AD. Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter. J Neurooncol 2001;51:19-24. (Pubitemid 32321897)
21. Kreklau EL, Kurpad C, Williams DA, Erickson LC. Prolonged inhibition of O (6)-methylguanine DNA methyltransferase in human tumor cells by O (6)-benzylguanine in vitro and in vivo. J Pharmacol Exp Ther 1999;291:1269-75.
22. Parchment RE, Gordon M, Grieshaber CK, Sessa C, Volpe D, Ghielmini M. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol 1998;9:357-64. (Pubitemid 28273026)
23. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66. (Pubitemid 30036349)
24. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004;10:3728-36. (Pubitemid 38697606)
25. 6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res 2007;13:6712-8. (Pubitemid 350206808)
26. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
27. ClinicalTrials.gov. Combination chemotherapy and radiation therapy in treating younger patients who are undergoing an autologous stem cell transplant for newly diagnosed gliomas. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00253487?term=autologous +stem+cell+transplant+for+newly+diagnosed+gliomas&rank=1 [-cited 2009 Sep. 21].
28. 6-benzylguanine using a transgenic model. Cancer Res 1996;56:1880-5.
29. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995;154:180-91.
30. Feuring-Buske M, Gerhard B, Cashman J, Humphries RK, Eaves CJ, Hogge DE. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 2003;17:760-3. (Pubitemid 36519373)
31. Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, Wilhelm JS, et al. Microenvironment determines lineage fate in a human model of MLLAF9 leukemia. Cancer Cell 2008;13:483-95. (Pubitemid 351763903)
32. Andre MC, Erbacher A, Gille C, Schmauke V, Goecke B, Hohberger A, et al. Long-term human CD34 (+) stem cell-engrafted nonobese diabetic/SCID/IL-2Rgamma (null) mice show impaired CD8 (+) T cell maintenance and a functional arrest of immature NK cells. J Immunol 2010;185:2710-20.
33. Chiu PP, Jiang H, Dick JE. Leukemia-initiating cells in human Tlymphoblastic leukemia exhibit glucocorticoid resistance. Blood 2010;116:5268-79.
34. Hayakawa J, Hsieh MM, Anderson DE, Phang O, Uchida N, Washington K, et al. The assessment of human erythroid output in NOD/SCID mice reconstituted with human hematopoietic stem cells. Cell Transplant 2010;19:1465-73.
35. Liu C, Chen BJ, Deoliveira D, Sempowski GD, Chao NJ, Storms RW. Progenitor cell dose determines the pace and completeness of engraftment in a xenograft model for cord blood transplantation. Blood 2010;116:5518-27.
36. McDermott SP, Eppert K, Lechman ER, Doedens M, Dick JE. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 2010;116:193-200.
37. Notta F, Doulatov S, Dick JE. Engraftment of human hematopoietic stem cells is more efficient in female NOD/SCID/IL-2Rgc-null recipients. Blood 2010;115:3704-7.
38. + hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Hum Gene Ther 2009;20:1607-26.
39. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, Lanzavecchia A, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004;304:104-7. (Pubitemid 38451466)
40. Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T, Tomizawa M, et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma (null) humanized mice. Proc Natl Acad Sci U S A 2010;107:13022-7.
41. Estes ML, Mund JA, Mead LE, Prater DN, Cai S, Wang H, et al. Application of polychromatic flow cytometry to identify novel subsets of circulating cells with angiogenic potential. Cytometry A 2010;77:831-9.
42. Collins LS, Dorshkind K. A stromal cell line from myeloid long-term bone marrow cultures can support myelopoiesis and B lymphopoiesis. J Immunol 1987;138:1082-7. (Pubitemid 17017888)
43. Suzuki J, Fujita J, Taniguchi S, Sugimoto K, Mori KJ. Characterization of murine hemopoietic-supportive (MS-1 and MS-5) and non-supportive (MS-K) cell lines. Leukemia 1992;6:452-8.
44. Takakura N, Kodama H, Nishikawa S. Preferential proliferation of murine colony-forming units in culture in a chemically defined condition with a macrophage colony-stimulating factor-negative stromal cell clone. J Exp Med 1996;184:2301-9.
45. Wineman J, Moore K, Lemischka I, Muller-Sieburg C. Functional heterogeneity of the hematopoietic microenvironment: rare stromal elements maintain long-term repopulating stem cells. Blood 1996;87:4082-90. (Pubitemid 26152252)
46. Namikawa R, Weilbaecher KN, Kaneshima H, Yee EJ, McCune JM. Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med 1990;172:1055-63. (Pubitemid 20343205)
47. Fraser CC, Kaneshima H, Hansteen G, Kilpatrick M, Hoffman R, Chen BP. Human allogeneic stem cell maintenance and differentiation in a long-term multilineage SCID-hu graft. Blood 1995;86:1680-93.
48. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007;131:324-36. (Pubitemid 47592917)
49. Angelopoulou M, Novelli E, Grove JE, Rinder HM, Civin C, Cheng L, et al. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol 2003;31:413-20. (Pubitemid 36579367)
50. Cruet-Hennequart S, Prendergast AM, Barry FP, Carty MP. Human mesenchymal stem cells (hMSCs) as targets of DNA damaging agents in cancer therapy. Curr Cancer Drug Targets 2010;10:411-21.
51. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343-59. (Pubitemid 30135902)